title: Medical Management of Meningiomas: Current Status, Failed Treatments, and Promising Horizons.
abstract: Meningiomas are benign tumors of the central nervous system, with low recurrence risk for World Health Organization (WHO) grade I lesions but a high risk for WHO grade II and III lesions. Current standard treatments include maximum safe surgical resection when indicated and radiation. Only three systemic therapies alpha-interferon, somatostatin receptor agonists, and vascular endothelial growth factor inhibitors are currently recommended by the National Comprehensive Cancer Network for treatment of recurrent meningioma. This paper aims to review medical approaches in the treatment of meningiomas.
authors.affiliation: Department of Neurosurgery, Clinical Neurosciences Center, University of Utah, 175 N. Medical Drive East, Salt Lake City, UT 84132, USA.
authors.forename: Michael
authors.initials: M
authors.lastname: Karsy
authors.affiliation: Department of Neurosurgery, Clinical Neurosciences Center, University of Utah, 175 N. Medical Drive East, Salt Lake City, UT 84132, USA.
authors.forename: Jian
authors.initials: J
authors.lastname: Guan
authors.affiliation: Department of Oncological Sciences, Huntsman Cancer Institute, University of Utah, 2000 Circle of Hope, Salt Lake City, UT 84112, USA.
authors.forename: Adam
authors.initials: A
authors.lastname: Cohen
authors.affiliation: Department of Neurosurgery, Clinical Neurosciences Center, University of Utah, 175 N. Medical Drive East, Salt Lake City, UT 84132, USA; Department of Oncological Sciences, Huntsman Cancer Institute, University of Utah, 2000 Circle of Hope, Salt Lake City, UT 84112, USA.
authors.forename: Howard
authors.initials: H
authors.lastname: Colman
authors.affiliation: Department of Neurosurgery, Clinical Neurosciences Center, University of Utah, 175 N. Medical Drive East, Salt Lake City, UT 84132, USA; Department of Oncological Sciences, Huntsman Cancer Institute, University of Utah, 2000 Circle of Hope, Salt Lake City, UT 84112, USA; Department of Radiation Oncology, Huntsman Cancer Institute, University of Utah, 2000 Circle of Hope, Salt Lake City, UT 84112, USA. Electronic address: randy.jensen@hsc.utah.edu.
authors.forename: Randy L
authors.initials: RL
authors.lastname: Jensen
mesh_terms: D003131:Combined Modality Therapy; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use; D008577:Meningeal Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000628:therapy; D008579:Meningioma / Q000188:drug therapy* / Q000235:genetics / Q000628:therapy; D009154:Mutation; D009389:Neovascularization, Pathologic / Q000188:drug therapy; D020794:Receptor Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D013004:Somatostatin / Q000031:analogs & derivatives / Q000627:therapeutic use; D017211:Treatment Failure
chemical_list: D013004:Somatostatin; D020794:Receptor Protein-Tyrosine Kinases; D006918:Hydroxyurea
keywords: Genetics; Medical management; Meningiomas; Targeted treatment